[go: up one dir, main page]

BR9810508A - Compound, pharmaceutical composition and method of treating a disorder - Google Patents

Compound, pharmaceutical composition and method of treating a disorder

Info

Publication number
BR9810508A
BR9810508A BR9810508-6A BR9810508A BR9810508A BR 9810508 A BR9810508 A BR 9810508A BR 9810508 A BR9810508 A BR 9810508A BR 9810508 A BR9810508 A BR 9810508A
Authority
BR
Brazil
Prior art keywords
disorders
disorder
treating
compound
pharmaceutical composition
Prior art date
Application number
BR9810508-6A
Other languages
Portuguese (pt)
Inventor
Richard G Wilde
Rajagtopal Bakthavatchalam
James P Beck
Argyrios G Arvanitis
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of BR9810508A publication Critical patent/BR9810508A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<B>"COMPOSTO, COMPOSIçãO FARMACêUTICA E MéTODO DE TRATAMENTO DE UMA DESORDEM"<D> A presente invenção refere-se a antagonistas do fator de liberação de corticotropina (CRF) da fórmula (I) e sua utilização no tratamento de desordens psiquiátricas e doenças neurológicas, desordens relacionadas com ansiedade, desordens por tensão pós-traumática, paralisia supranuclear e desordens alimentares, bem como tratamento de doenças imunológicas, cardiovasculares ou cardíacas e hipersensibilidade do cólon associada a distúrbios psicopatológicos e tensão em mamíferos.<B> "COMPOUND, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING A DISORDER" <D> The present invention relates to antagonists of the corticotropin releasing factor (CRF) of the formula (I) and its use in the treatment of psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorders, supranuclear palsy and eating disorders, as well as treatment of immune, cardiovascular or cardiac diseases and colon hypersensitivity associated with psychopathological disorders and tension in mammals.

BR9810508-6A 1997-07-03 1998-07-02 Compound, pharmaceutical composition and method of treating a disorder BR9810508A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5162897P 1997-07-03 1997-07-03
US8066598P 1998-04-03 1998-04-03
PCT/US1998/013913 WO1999001454A1 (en) 1997-07-03 1998-07-02 Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders

Publications (1)

Publication Number Publication Date
BR9810508A true BR9810508A (en) 2000-09-05

Family

ID=26729655

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9810508-6A BR9810508A (en) 1997-07-03 1998-07-02 Compound, pharmaceutical composition and method of treating a disorder

Country Status (20)

Country Link
US (3) US6143743A (en)
EP (1) EP0994877A1 (en)
JP (1) JP2002507996A (en)
KR (1) KR20010014431A (en)
CN (1) CN1268137A (en)
AR (1) AR016307A1 (en)
AU (1) AU746706B2 (en)
BR (1) BR9810508A (en)
CA (1) CA2294117A1 (en)
EE (1) EE04280B1 (en)
HR (1) HRP980375A2 (en)
HU (1) HUP0100179A3 (en)
IL (1) IL133800A0 (en)
MY (1) MY132871A (en)
NO (1) NO316119B1 (en)
NZ (1) NZ502642A (en)
PL (1) PL337888A1 (en)
SK (1) SK179899A3 (en)
TW (1) TW589309B (en)
WO (1) WO1999001454A1 (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU738581B2 (en) * 1996-12-11 2001-09-20 Aventis Pharmaceuticals Inc. Preparation of (1S-(1a,2b,3b,4a(S*)))-4-(7-((1-(3-chloro-2- thienyl) methyl)propyl)amino)-3H-imidazo(4,5-b)pyridin-3-yl )-N-ethyl-2,3-dihydroxycylopentanecarboxamide
US6365589B1 (en) * 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US6124463A (en) * 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
EA004515B1 (en) * 1998-12-23 2004-04-29 Дюпон Фармасьютикалз Компани Nitrogen containing heterobicycles as factor xa inhibitors
US6271380B1 (en) * 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
WO2000059907A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
WO2000059908A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
US6432989B1 (en) * 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
WO2001044248A1 (en) * 1999-12-17 2001-06-21 Bristol-Myers Squibb Pharma Company Imidazopyrimidinyl and imidazopyridinyl derivatives
EP1293213A1 (en) * 2000-02-14 2003-03-19 Japan Tobacco Inc. Preventives/remedies for postoperative stress
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AR028782A1 (en) * 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd TETRAHYDROPIRIDINE OR PIPERIDINE HETEROCICLIC DERIVATIVES
AU2001276903A1 (en) 2000-07-14 2002-01-30 Bristol-Myers Squibb Pharma Company Imidazo(1,2-a)pyrazines for the treatment of neurological disorders
EP1854798A3 (en) 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
GB0100623D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
US6888004B2 (en) 2001-01-26 2005-05-03 Bristol-Myers Squibb Company Imidazolyl derivatives as corticotropin releasing factor inhibitors
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20030125330A1 (en) 2001-03-13 2003-07-03 Gilligan Paul J. 4 - (2-butylamino) - 2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-yl) pyrazolo- [1,5-A] - 1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
HUP0401292A3 (en) 2001-04-27 2011-01-28 Eisai R & D Man Co Pyrazolo[1,5-a]pyridines, pharmaceutical compositions containing the same and process for preparation thereof
CA2446980A1 (en) 2001-05-14 2002-11-21 Argyrios G. Arvanitis Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
WO2003005969A2 (en) 2001-07-12 2003-01-23 Bristol-Myers Squibb Pharma Company Tetrahydropurinones as corticotropin releasing factor
US7276526B2 (en) 2001-07-13 2007-10-02 Bristol-Myers Squibb Pharma Company Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
JP4397691B2 (en) * 2001-10-30 2010-01-13 コンフォーマ・セラピューティクス・コーポレイション Purine analogs having HSP90 inhibitory activity
WO2003043637A1 (en) 2001-11-20 2003-05-30 Bristol-Myers Squibb Pharma Company 3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands
EP1467979B1 (en) 2001-12-19 2008-08-13 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof modulators of nuclear hormone receptor function
ES2262996T3 (en) 2002-01-07 2006-12-01 Eisai Co., Ltd. DEAZAPURINAS AND ITS USES.
WO2003078435A1 (en) 2002-03-13 2003-09-25 Pharmacia & Upjohn Company Llc Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators
US6884880B2 (en) * 2002-08-21 2005-04-26 Ash Stevens, Inc. Process for the preparation of 9-β-anomeric nucleoside analogs
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
SI1555265T1 (en) 2002-10-22 2009-06-30 Eisai R&D Man Co Ltd 7-phenyl pyrazolopyridine compounds
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
ATE418555T1 (en) 2003-04-09 2009-01-15 Biogen Idec Inc A2A ADENOSIN RECEPTOR ANTAGONISTS
WO2004092170A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
KR20060070572A (en) * 2003-09-18 2006-06-23 콘포마 세러퓨틱스 코포레이션 Novel Heterocyclic Compounds as HPS90-Inhibitors
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
DE102004037554A1 (en) * 2004-08-03 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituted 8-aminoalkylthio-xanthines, process for their preparation and their use as medicaments
DE102004039507A1 (en) * 2004-08-14 2006-03-02 Sanofi-Aventis Deutschland Gmbh Substituted 8-aminoalkoxi-xanthines, process for their preparation and their use as medicaments
US7238702B2 (en) * 2005-02-10 2007-07-03 Bristol-Myers Squibb Company Dihydroquinazolinones as 5HT modulators
EP1869027A4 (en) 2005-03-30 2010-06-23 Conforma Therapeutics Corp Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors
WO2007016353A2 (en) * 2005-07-28 2007-02-08 Bristol-Myers Squibb Company Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
GB0519245D0 (en) * 2005-09-20 2005-10-26 Vernalis R&D Ltd Purine compounds
EP1937258A2 (en) * 2005-09-23 2008-07-02 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
EP3443958A1 (en) 2006-11-22 2019-02-20 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
US8372859B2 (en) * 2007-04-11 2013-02-12 Merck, Sharp & Dohme Corp. CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups
CN104119336B (en) 2007-10-05 2016-08-24 维拉斯通股份有限公司 The substituted purine derivative of pyrimidine
MY152687A (en) 2008-04-15 2014-10-31 Eisai R&D Man Co Ltd 3-phenylpyrazolo[5,1-b]thiazole compound
US20110152313A1 (en) * 2008-06-20 2011-06-23 Macquarie University Synthesis of ageladine a and analogs thereof
FR2933982A1 (en) * 2008-07-18 2010-01-22 Sanofi Aventis NOVEL IMIDAZO-1,2-A! PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS MET INHIBITORS
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
US8754080B2 (en) 2009-04-03 2014-06-17 Verastem, Inc. Pyrimidine substituted purine compounds as kinase (S) inhibitors
AR078521A1 (en) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd PIRAZOLOTIAZOL COMPOUND
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2012044537A1 (en) 2010-10-01 2012-04-05 Bristol-Myers Squibb Company Substituted benzimidazole and imidazopyridine compounds useful as cyp17 modulators
US9266880B2 (en) 2010-11-12 2016-02-23 Bristol-Myers Squibb Company Substituted azaindazole compounds
EP2760870B1 (en) 2011-09-27 2016-05-04 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
RU2014149136A (en) * 2012-05-08 2016-07-10 Мерк Шарп И Доум Корп. TETRAHYDRONAFTHYRIDINE AND RELATED Bicyclic Compounds for Inhibition of Rorγ Activity and Treatment of a Disease
EP2818472A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators
US9920052B2 (en) * 2013-12-09 2018-03-20 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of TNF activity
TWI731317B (en) * 2013-12-10 2021-06-21 美商健臻公司 Tropomyosin-related kinase (trk) inhibitors
WO2015088885A1 (en) * 2013-12-11 2015-06-18 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
JP6645695B2 (en) * 2014-10-14 2020-02-14 中尾　洋一 Imidazopyridine amine compound, its production method and use
MA40698A3 (en) 2014-12-18 2020-01-31 Genzyme Corp Pharmaceutical Formulations of Tropomyosin Associated Kinase Inhibitors (trk)
MY186368A (en) * 2015-07-20 2021-07-16 Genzyme Corp Colony stimulating factor-1 receptor (csf-1r) inhibitors
EP3628044B1 (en) * 2017-05-15 2023-11-22 The Regents of The University of Michigan Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
WO2023119233A1 (en) * 2021-12-23 2023-06-29 Molecure S.A. Deubiquitinase inhibitors and methods of use thereof

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015473A (en) * 1984-01-30 1991-05-14 Pfizer Inc. 6-(substituted)methylenepenicillanic and 6-(substituted)hydroxymethylpenicillanic acids and derivatives thereof
GB8601160D0 (en) * 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
US4859672A (en) * 1986-10-29 1989-08-22 Rorer Pharmaceutical Corporation Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone
US5495010A (en) * 1987-04-17 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services Acid stable purine dideoxynucleosides
US4999363A (en) * 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
DE68906324T2 (en) * 1988-07-19 1993-10-21 Du Pont Substituted phenyltriazolopyrimidines as herbicides.
AU618158B2 (en) * 1989-01-07 1991-12-12 Bayer Aktiengesellschaft New substituted pyrido(2,3-d)pyrimidines
FR2643903A1 (en) * 1989-03-03 1990-09-07 Union Pharma Scient Appl NOVEL BENZIMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING SAME, SYNTHESIS INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, IN PARTICULAR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES, AND DUODENIAL ULCERS
GB8906168D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
DE3916469A1 (en) * 1989-05-20 1990-11-22 Basf Ag SULPHONAMID
IE64514B1 (en) * 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
US5102880A (en) * 1989-05-30 1992-04-07 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
IL94390A (en) * 1989-05-30 1996-03-31 Merck & Co Inc Di-substituted imidazo fused 6-membered nitrogen-containing heterocycles and pharmaceutical compositions containing them
US5157026A (en) * 1989-05-30 1992-10-20 Merck & Co., Inc. Oxo-purines as angiotensin II antagonists
DE3921271A1 (en) * 1989-06-29 1991-01-03 Basf Ag New purine-8-sulphonamide derivs. - useful as herbicides and plant growth regulators
US5145959A (en) * 1989-07-18 1992-09-08 Bayer Aktiengesellschaft Substituted pyrido (2,3-d) pyrimidines as intermediates
EP0416740A3 (en) * 1989-08-08 1991-08-28 Beecham Group P.L.C. Novel compounds with renin-inhibiting activity
EP0415886A3 (en) * 1989-08-30 1991-10-23 Ciba-Geigy Ag Aza compounds
GB8927872D0 (en) * 1989-12-08 1990-02-14 Beecham Group Plc Pharmaceuticals
EP0434038A1 (en) * 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Fused imidazole derivatives, their production and use
US5587470A (en) * 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
JPH04235974A (en) * 1990-06-08 1992-08-25 Roussel Uclaf New benzimidazole derivatives, process for producing same, obtained new intermediates, use thereof as medicines and pharmaceutical compositions containing same
WO1991019715A1 (en) * 1990-06-15 1991-12-26 G.D. Searle & Co. 1H-SUBSTITUTED-IMIDAZO[4,5-d]PYRIDAZINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
DE4023369A1 (en) * 1990-07-23 1992-01-30 Thomae Gmbh Dr K New 1-bi:phenylyl:methyl benzimidazole derivs.
US5210092A (en) * 1990-09-25 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Angiotensin ii antagonizing heterocyclic derivatives
US5260322A (en) * 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
CA2062558A1 (en) * 1991-03-08 1992-09-09 Prasun K. Chakravarty Heterocyclic compounds bearing acidic functional groups as angiotensin ii antagonists
CH681806A5 (en) * 1991-03-19 1993-05-28 Ciba Geigy Ag
US5128327A (en) * 1991-03-25 1992-07-07 Merck & Co., Inc. Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle
TW274551B (en) * 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
US5332820A (en) * 1991-05-20 1994-07-26 E. I. Du Pont De Nemours And Company Dibenzobicyclo(2.2.2) octane angiotensin II antagonists
WO1992022552A1 (en) * 1991-06-14 1992-12-23 The Upjohn Company IMIDAZO[1,5-a]QUINOXALINES
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
WO1993003033A1 (en) * 1991-07-26 1993-02-18 G. D. Searle & Co. CARBONATE-SUBSTITUTED IMIDAZO[4,5-d] PYRIDAZINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
DE4129603A1 (en) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K CONDENSED 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THESE COMPOUNDS
TW300219B (en) * 1991-09-14 1997-03-11 Hoechst Ag
US5178997A (en) * 1991-09-20 1993-01-12 Eastman Kodak Company Process for the preparation of high chloride tabular grain emulsions (II)
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
US5330989A (en) * 1991-10-24 1994-07-19 American Home Products Corporation Heterocycles substituted with biphenyl-3-cyclobutene-1,2-dione derivatives
US5332814A (en) * 1991-11-12 1994-07-26 Ciba-Geigy Corporation Process for the preparation of carbacyclic nucleosides, and intermediates
US5176991A (en) * 1992-01-27 1993-01-05 Eastman Kodak Company Process of preparing for photographic use high chloride tabular grain emulsion
GB2263637A (en) * 1992-01-28 1993-08-04 Merck & Co Inc Substituted imidazo-fused 6-membered carbocycle or heterocycle as neurotensin antagonists
JPH05213754A (en) * 1992-02-03 1993-08-24 Kyowa Hakko Kogyo Co Ltd Anti-ulcer agent
IT1254798B (en) * 1992-02-18 1995-10-11 Snam Progetti Process for restarting the operation of a conduit containing highly sterile fluids and devices for implementing this
DE4207904A1 (en) * 1992-03-12 1993-09-16 Thomae Gmbh Dr K SUBSTITUTED BENZIMIDAZOLYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
JPH05287209A (en) * 1992-04-09 1993-11-02 Hitachi Chem Co Ltd Fluorescent labelling dye, biogenic substance labelled with the same, and reagent containing them
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
WO1993023409A1 (en) * 1992-05-21 1993-11-25 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivative
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
EP0577558A2 (en) * 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
JP3866279B2 (en) * 1992-09-28 2007-01-10 リサーチ コーポレイション テクノロジーズ，インコーポレイテッド Novel reagents for peptide ligation
TW251284B (en) * 1992-11-02 1995-07-11 Pfizer
GB2272899A (en) * 1992-11-30 1994-06-01 Du Pont Merck Pharma Angiotensin-11 receptor blocking cycloalkylbenzylimidazoles
US5376666A (en) * 1992-11-30 1994-12-27 The Du Pont Merck Pharmaceutical Company Angiotension-II receptor blocking, azacycloalkyl or azacycloalkenyl
CA2400368A1 (en) * 1992-12-02 1994-06-09 Allen J. Duplantier Catechol diethers as selective pde iv inhibitors
CA2154681A1 (en) * 1993-02-03 1994-08-18 Mark David Erion Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
DE4304455A1 (en) * 1993-02-15 1994-08-18 Bayer Ag Heterocyclic substituted phenyl-cyclohexane-carboxylic acid derivatives
US5374638A (en) * 1993-03-19 1994-12-20 Merck & Co., Inc. Six membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives used to treat asthma
DE4309969A1 (en) * 1993-03-26 1994-09-29 Bayer Ag Substituted hetero-fused imidazoles
US5338740A (en) * 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
CA2131680C (en) * 1993-09-17 2006-11-07 Gerhard Stucky Process for preparing imidazopyridine derivatives
CA2131134A1 (en) * 1993-09-17 1995-03-18 Gerhard Stucky Process for preparing imidazopyridine derivatives
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
CA2136885A1 (en) * 1993-12-01 1995-06-02 David L. Kuo Process for preparing imidazopyridine derivatives
EP0741741B1 (en) * 1994-01-26 2002-08-28 Novartis AG Modified oligonucleotides
KR0151816B1 (en) * 1994-02-08 1998-10-15 강박광 Novel substituted pyridyl imidazole derivatives and preparation methods thereof
WO1995021836A1 (en) * 1994-02-10 1995-08-17 Pfizer Inc. 5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists
EP0679657B1 (en) * 1994-04-27 2003-07-09 Novartis AG Nucleosides and oligonucleotides containing 2'-ether groups
US5424432A (en) * 1994-05-26 1995-06-13 Merck & Co., Inc. Process for the preparation of imidazolutidine
AU2265495A (en) * 1994-06-06 1996-01-04 Pfizer Inc. Substituted pyrazoles having corticotropin-releasing factor (crf) antagonist activity
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
KR0151819B1 (en) * 1994-06-11 1998-10-15 강박광 Novel pyridylimidazole derivatives substituted with pyridyl n-oxide and process for the preparation thereof
EP0765327B1 (en) * 1994-06-16 1999-07-21 Pfizer Inc. Pyrazolo and pyrrolopyridines
SE9402431D0 (en) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE504459C2 (en) * 1994-07-15 1997-02-17 Astra Ab Process for the preparation of substituted sulfoxides
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US5563143A (en) * 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution
GB9423970D0 (en) * 1994-11-28 1995-01-11 Astra Ab Oxidation
AU4303996A (en) * 1994-12-19 1996-07-10 Novartis Ag 6'-substituted carbocyclic nucleosides
SE9500422D0 (en) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (en) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
WO1997008150A1 (en) * 1995-08-22 1997-03-06 The Du Pont Merck Pharmaceutical Company Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors
DE19536891A1 (en) * 1995-10-04 1997-04-10 Basf Ag New amino acid derivatives, their production and use
DE19614533A1 (en) * 1996-04-12 1997-10-16 Basf Ag New alpha-hydroxy acid derivatives, their production and use
US6022978A (en) * 1996-06-11 2000-02-08 Pfizer Inc. Benzimidazole derivatives
CN1227554A (en) * 1996-08-28 1999-09-01 辉瑞大药厂 Substituted 6,5-hetero-bicyclic derivatives
AU6279598A (en) 1997-02-18 1998-09-08 Neurocrine Biosciences, Inc. Biazacyclic CRF antagonists

Also Published As

Publication number Publication date
MY132871A (en) 2007-10-31
NO996483D0 (en) 1999-12-27
TW589309B (en) 2004-06-01
HUP0100179A2 (en) 2001-11-28
IL133800A0 (en) 2001-04-30
HUP0100179A3 (en) 2002-12-28
AU746706B2 (en) 2002-05-02
CN1268137A (en) 2000-09-27
US6642230B2 (en) 2003-11-04
US6143743A (en) 2000-11-07
US6362180B1 (en) 2002-03-26
SK179899A3 (en) 2001-12-03
NO996483L (en) 2000-03-02
EE9900607A (en) 2000-08-15
HRP980375A2 (en) 1999-04-30
WO1999001454A1 (en) 1999-01-14
EE04280B1 (en) 2004-04-15
JP2002507996A (en) 2002-03-12
NO316119B1 (en) 2003-12-15
NZ502642A (en) 2002-06-28
KR20010014431A (en) 2001-02-26
CA2294117A1 (en) 1999-01-14
AR016307A1 (en) 2001-07-04
US20030114468A1 (en) 2003-06-19
EP0994877A1 (en) 2000-04-26
PL337888A1 (en) 2000-09-11
AU8181998A (en) 1999-01-25

Similar Documents

Publication Publication Date Title
BR9810508A (en) Compound, pharmaceutical composition and method of treating a disorder
BR9814458A (en) Compound, pharmaceutical composition and method of treating affective disorders
BR9908206A (en) Compound, pharmaceutical composition and method of treating malfunctions and diseases in mammals
ES2150482T3 (en) PIRAZOLOPIRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR.
KR100521829B1 (en) Compositions and Methods for the Treatment of Alzheimer&#39;s Disease, Central Nervous System Injury, and Inflammatory Diseases
ATE209492T1 (en) USE OF 1,2,4-TRIAZOLO(1,5-C)PYRIMIDINE HETEROCYCLIC ANALOGUE FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF CEREBROVASCULAR DISORDERS
BR0209575A (en) Pyrazinones, pyridines and pyrimidines substituted as corticotropin releasing factor binders
PL342078A1 (en) Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas
BR9708261A (en) Crf antagonist compound, pharmaceutical composition, treatment method for disorders, process for the production of pyrimidine, pyrimidone, method for the production of a compound and compound
FI971955A7 (en) Induction of dopaminergic cells in vitro
DE69726724D1 (en) TETRAHYDROPTERIDINE AND PYRIDYLPIPERAZINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
IL132293A0 (en) Use of lactoferin in the treatment of allergen induced disorders
BG101213A (en) Synthetic stimulation amino acids
BR9712259A (en) Colostrininin, use of it, processes of treating disorders of the central nervous system and / or the immune system, of preparing colostrum of mammalian colostrum and of producing a pharmaceutical composition, pharmaceutical composition, dietary supplement, nanopeptide, and use of it.
BR0208357A (en) Compound, pharmaceutical composition, corticotropin-releasing factor (crf) receptor antagonization method, dysfunction treatment method, ligand screening method, crf receptor detection method, crf binding inhibition method, article industrialized and uses of compost
DE69820053D1 (en) INTERFERENCE NOTOCORD TO REDUCE SYMPTOMS / TREATMENT OF ARTHRITIS
WO2001057042A3 (en) 4-pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy
BR9607443A (en) Compound of 4-aminotetrahydrobenzisoxazole or -isatiazole pharmaceutical composition and use of the compound
GR3017358T3 (en) 5-Aryl-3H-1,2,4-triazol-3-ones and their use as anticonvulsants.
DK671187D0 (en) USE OF 5-ARYL-3H-1,2,4-TRIAZOL-3-ONER IN TREATMENT OF NEURODEGENERATIVE DISEASES
DE59609977D1 (en) TRAPIDIL FOR USE IN THE THERAPY OF IMMUNO-MODULATABLE INFLUENCES
NO973876D0 (en) Human DNase I variants
MY141511A (en) Azolo triazines and pyrimidines
ES2146530A1 (en) Process using the growth factor igf-1 in the manufacture of compositions that are useful in the treatment of cerebellar ataxia
CA2532925A1 (en) Azolo triazines and pyrimidines

Legal Events

Date Code Title Description
TE Change of address
B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1908 DE 31/07/2007.